Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: The EPIC-Norfolk prospective population study

Heart

Volumn 95, Issue 20, 2009, Pages 1682-1687

  Rana, J S ^a,b   Cote, M ^c   Despres J P ^c   Sandhu, M S ^d   Talmud, P J ^e   Ninio, E ^f   Wareham, N J ^g   Kastelein, J J P ^b   Zwinderman, A H ^b   Khaw, K T ^d   Boekholdt, S M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c LAVAL UNIVERSITY   (Canada)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^f INSERM   (France)

^g MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADIPONECTIN; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; SECRETORY PHOSPHOLIPASE A2;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; DISEASE MARKER; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; MALE; NORMAL HUMAN; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; UNITED KINGDOM;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADIPONECTIN; AGED; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHEMOTACTIC FACTORS; CORONARY ARTERY DISEASE; FEMALE; FIBRINOGEN; GROUP II PHOSPHOLIPASES A2; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PEROXIDASE; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 70349614412     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2009.170134     Document Type: Article

References (32)

1. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847 (Pubitemid 28213628)
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
3. Fortmann SP, Ford E, Criqui MH, et al. CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: report from the population science discussion group. Circulation 2004;110:e554-9.
4. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
5. Currie CJ, Poole CD, Conway P. Evaluation of the association between the first observation and the longitudinal change in C-reactive protein, and all-cause mortality. Heart 2008;94:457-462
6. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-1397 (Pubitemid 38419992)
7. van der Meer IM, de Maat MP, Kiliaan AJ, et al. The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study. Arch Intern Med 2003;163:1323-1328 (Pubitemid 36676197)
8. Shlipak MG, Fried LF, Cushman M, et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 2005;293:1737-1745 (Pubitemid 40491299)
9. Wilson PW, Nam BH, Pencina M, et al. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med 2005;165:2473-2478 (Pubitemid 41720008)
10. Rutter MK, Meigs JB, Sullivan LM, et al. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004;110:380-385
11. Koenig W, Lowel H, Baumert J, et al. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004;109:1349-1353 (Pubitemid 38387819)
12. Greenland P, O'Malley PG. When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk. Arch Intern Med 2005;165:2454-2456 (Pubitemid 41720004)
13. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007;115:928-935 (Pubitemid 46294733)
14. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 2006;145:21-29 (Pubitemid 46780601)
15. Day N, Oakes S, Luben R, et al. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer 1999;80(Suppl 1):95-103.
16. Boekholdt SM, Peters RJ, Day NE, et al. Macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coronary artery disease in adults without prior myocardial infarction or stroke: the EPIC-Norfolk Prospective Population study. Am J Med 2004;117:390-397
17. Boekholdt SM, Hack CE, Sandhu MS, et al. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. Atherosclerosis 2006;2006:415-22.
18. Meuwese MC, Stroes ES, Hazen SL, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007;50:159-165 (Pubitemid 47002189)
19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
20. Bruins P, te Velthuis H, Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 1997;96:3542-3548
21. Mackness B, Durrington P, McElduff P, et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003;107:2775-2779 (Pubitemid 36705985)
22. Boekholdt SM, Keller TT, Wareham NJ, et al. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. Arterioscler Thromb Vasc Biol 2005;25:839-846
23. Blankenberg S, Stengel D, Rupprecht HJ, et al. Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. J Lipid Res 2003;44:1381-1386 (Pubitemid 37279620)
24. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957;17:237-246
25. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-172
26. Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007;297:611-619 (Pubitemid 46257283)
27. Wilson PWF, Michael Pencina M, Jacques P. C-reactive protein and reclassification of cardiovascular risk in the framingham heart study. Circ Cardiovasc Qual Outcomes 2008;1:92-97
28. Rose G. Strategy of prevention: lessons from cardiovascular disease. BMJ 1981;282:1847-1851 (Pubitemid 11047749)
29. Dickinson BD, Havas S. For the Council on Science and Public Health AMA. Reducing the population burden of cardiovascular disease by reducing sodium intake: a report of the council on science and public health. Arch Intern Med 2007;167:1460-1468
30. Shah T, Casas JP, Cooper JA, et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol 2009;38:217-231
31. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006;355:2631-2639 (Pubitemid 44969122)
32. Simmons RK, Sharp S, Boekholdt SM, et al. Evaluation of the Framingham risk score in the European Prospective Investigation of Cancer-Norfolk cohort: does adding glycated hemoglobin improve the prediction of coronary heart disease events? Arch Intern Med 2008;168:1209-1216